

Press release
July 1, 2010
Gothenburg, Sweden

Less bleeding and pain with Vitrolife's follicle aspiration needle according to multicenter study

The Swemed Sense™ needle gives less pain and bleeding compared with a conventional needle for oocyte aspiration. The results of the multicenter study carried out in Sweden were presented yesterday during the ongoing ESHRE conference in Rome.

"The follicle aspiration needle Swemed Sense™ makes it possible to work in a new way, which is more favourable for patients, and at the same time it meets all the other quality requirements for a follicle aspiration needle", says Dr. Matts Wikland, who works at Fertility Center Scandinavia in Gothenburg, when he presented the results of the study at the annual meeting of ESHRE, the European Society of Human Reproduction and Embryology. The conference has been ongoing since Sunday and has gathered approximately 8,000 international delegates.

The study has investigated how the sensation of pain in women undergoing oocyte aspiration before IVF differs if a new needle with a thinner tip (Swemed Sense™) is used, compared with a conventional, thicker needle. The results show that a needle with a thinner tip give less pain and bleeding compared with a conventional needle. The time taken to retrieve oocytes and the number of undamaged oocytes were not different in the two groups.

July 1, 2010
Gothenburg, Sweden
Magnus Nilsson, CEO

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 170 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.